![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Levetiracetam is an antiepileptic drug approved for use as an adjunctive agent in partial-onset seizures in adults. This approval was recently extended to children over 4 years of age. Among the currently approved antiepileptic drugs, levetiracetam is unique in its mechanism of action. Its CNS binding site, the synaptic vesicle protein SV2A, was discovered recently. Binding at this site may be important for the antiseizure activity of levetiracetam and the role of this binding site and its modulation by levetiracetam is an area of active research in epilepsy. Levetiracetam is generally safe, has near to ideal pharmacokinetics and does not interact with other medications. The most serious adverse events are behavioral in nature. Recent studies suggest that levetiracetam may be effective in generalized epilepsies, status epilepticus, pain and selected movement disorders. Intriguing studies using the kindling model of epilepsy suggest that levetiracetam may protect against the development of kindling and chronic epilepsy. A parenteral formulation of levetiracetam may soon become available and may lead to larger studies of levetiracetam in status epilepticus.